Epidermal growth factor receptor-Mutated Non-small-cell Lung Cancer with Intracranial Progressions and Stable Extracranial Diseases Benefit from Osimertinib Regardless of T790M Mutational Status

OBJECTIVES: Osimertinib has exhibited promising central nervous system (CNS) efficacy in Epidermal growth factor receptor (EGFR)-mutated advanced non-small-cell lung cancer (NSCLC) patients. In real-world clinical practice, patients would turn to plasma genotyping or take osimertinib blindly after C...

Descripción completa

Detalles Bibliográficos
Autores principales: Liao, Jun, Huang, Yihua, Gan, Jiadi, Pang, Lanlan, Ali, Wael A. S., Yang, Yunpeng, Chen, Likun, Zhang, Li, Fang, Wenfeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: SAGE Publications 2022
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883386/
https://www.ncbi.nlm.nih.gov/pubmed/35201951
http://dx.doi.org/10.1177/10732748221081360

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8883386/
https://www.ncbi.nlm.nih.gov/pubmed/35201951
http://dx.doi.org/10.1177/10732748221081360

Ejemplares similares